Sloan-Kettering Institute for Cancer Research

Cornell University

Imclone System Incorporated

Malcolm A S Moore

Samuel J Danishefsky

David C Dorn

Kaida Wu

Ting-Chao Chou

Janice L Gabrilove

Karl Welte

Mihirbaran Mandal

Erich Platzer

Ana E Gabarda

Huajin Dong

Alexey Rivkin

Fumihiko Yoshimura

Shahin Rafii

Jochen Buck

Christoph Gaul

Roland Mertelsmann

Karl Henry Nocka

Peter Besmer

Jón T Njardarson

Larry Witte

Roland Mertelsman

In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis. 

Migrastatin analogs in the treatment of cancer

The present invention provides compounds having formula (I): (I) wherein n, R-R, R-R, Q, Yand Yare as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis.

Isomigrastatin analogs in the treatment of cancer

The present invention provides compounds of formula (I): 

Synthesis of epothilones, intermediates thereto, analogues and uses thereof

The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).

The invention is directed to a purified population of mammalian endothelial, muscle, or neural stem cells. The invention further provides methods for isolating such populations of cells; methods for using such populations of cells for treating mammals; methods for making vectors for gene therapy; and methods for carrying out gene therapy with such vectors.

Purified populations of stem cells

Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5&#xd7;10U/mg protein.

Human pluripotent hematopoietic colony stimulating factor, method of production and use

Highly purified Pluripotent hematopoietic colon-stimulating factor (pluripotent CSF), a glycoprotein (MW ) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparent homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM) early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is U/mg protein.

Human pluripotent hematopoietic colony stimulating factor, method of use

A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

C-kit ligand-based method for expanding peripheral blood cell levels

Growing community of inventors

New York, NY, United States of America

Malcolm A S Moore